The human microbiome market is projected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024. This market is projected to grow at a CAGR of 31.5% over the forecast period. The primary drivers behind the expansion of this industry are the technological advancement in microbiome sequencing, the collaborative efforts between the microbiome industry, organizations, and academia for microbiome research, and the increase in the number of startups and SMEs exploring the microbiome niche, and further opportunities such as the increase in demand for personalized medicine and the emergence of synbiotics may help drive the human microbiome market.
Download an Illustrative overview
The human microbiome market study covers probiotics, prebiotics, and synbiotics. Probiotics accounted for the largest share in the human microbiome market
An expanding segment in human microbiome therapeutics, probiotics are necessary to restore therefore preserving gut health by means of focused microbial treatments. Driven by growing consumer knowledge of the advantages of probiotics for gut health, immunity, and general wellness, the probiotics market has attracted major interest recently. For Instance, using antibiotics frequently results in severe dysbiosis by indiscriminately impacting both dangerous and helpful gut microorganisms.
Apart from probiotics, over the projection period, synbiotics are expected to have the highest CAGR. Combining prebiotics and probiotics, synbiotics improve gut health and balance the flora. Their evolution results in innovative product concepts and therapeutic alternatives, therefore stimulating more research, investment, and product launches. Emerging SMEs and startups are looking at the synbiotics niche capitalizing on the growing market trend. Companies like Seed Health, Inc. (US) concentrate on developing synbiotics for different diseases as dietary supplements.
By Disease, infectious diseases, gastrointestinal diseases, endocrine and metabolic disorders, and other diseases constitute the Human Microbiome market. The segment of gastrointestinal diseases held the biggest share in the human microbiome market in 2023. Gastrointestinal diseases include celiac disease, irritable bowel syndrome (IBS), lactose intolerance, chronic diarrhea, constipation, gastroesophageal reflux disease (GERD), and inflammatory bowel disease (IBD), among others. Several clinical trials are investigating the effect of human microbiome drugs and microbiome-based probiotics to alleviate the effects of gastrointestinal diseases such as NCT04970446 which investigates the effect of BIOMICTRA an approved FMT product in ulcerative colitis. The gastrointestinal disease segment within the human microbiome market is propelled by increasing demand for personalized therapies and supported by regulatory approvals and a large clinical pipeline and also validated by a robust pipeline of drugs investigating their role in treating these diseases.
By Type, bacterial consortia transplantation (BCT)/ fecal microbiota transplantation (FMT), live biotherapeutic products, and others segment the human microbiome market. BCT/ FMT accounted for the second largest market share driven by approved products in this segment by several prominent players in the human microbiome space. The segment with the second largest proportion of the human microbiome market in 2023 is the Live biotherapeutic products segment (LBPs). LBPs represent a novel class of medication derived from the human gut microbiome. These products contain live organisms, such as bacteria, and are intended for the prevention, treatment, or cure of diseases in humans.
Unlike vaccines, LBPs are generally not administered by injection. The increasing use of antibiotics, resulting in dysbiosis and antibiotic-resistant pathogens, further drives the market for LBPs. Additionally, the demand for personalized treatment solutions propels the development of LBPs designed to restore eubiosis and offer targeted therapies.
The human microbiome market is segmented by end users, hospitals and clinics, long-term care facilities, and other end users segment. The segment with the biggest share in the human microbiome market in 2023 was Hospitals and clinics. Hospitals are environments with strict clinical guidelines, legal mandates, and standards which guarantee that these therapies are carried out in a sterile, under control environment. To successfully execute operations like EMT and BCT, monitor patient outcomes, and control any possible consequences, hospitals have the required infrastructure—that is, specialized facilities and qualified medical experts. Hospitals also include Advanced diagnostic techniques and laboratory capacity which provides improved access and diagnosis for rapid treatment through microbiome based therapies. This improves the safety and efficacy of the treatments, therefore, hospitals are essential for their implementation in clinical practice.
North America is the largest regional market for Human Microbiomes in 2023, while Europe is the second-largest market. US was the major shareholder of revenue in this region along with highest CAGR. The development of US as a prominent player in this region can be attributed to availability of infrastructure for human microbiome product development, regulatory approval for niche products such as FMT, presence of prominent players in the human microbiome space along with the large investments across human microbiome market by organizations and the government. APAC was the fastest growing region in the human microbiome market. China was major contributor to the revenue of this region, mainly as a result of human microbiome market in china which is driven by investments across R&D, Emerging microbiome start-ups and SMEs, and aging population which demands for more advanced and personalized therapies. While, in the European human microbiome market UK and Germany majorly contribute to the revenue.
Key players in the Human Microbiome market are Nestle S.A. (Switzerland), Ferring Pharmaceuticals (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc (US), Pendulum (US), BioHM Health Inc. (US), Actial Farmaceutica SRL (Italy), Optibiotix Health plc (UK), Resbiotic (US), Infinant Health Inc (US), Biogaia AB (Sweden), and Exegi Pharma Llc (US).
Seres Therapeutics, Inc. (US)
Seres Therapeutics is one of the emerging players in the human microbiome market. The company’s microbiome therapeutics platform significantly reduces the time typically required to advance therapeutics to the clinic and, ultimately, to the market. The company focuses on R&D to launch advanced products in the market.
Ferring Pharmaceuticals (Switzerland)
Ferring Pharmaceutical’s revenue has seen a growth, owing to Ferring being the first company to receive approval for their fecal microbiota transplant product in the US which rendered them a key player in the human microbiome market space. They have emerged as a leading player through a combination of Organic and inorganic growth strategies bolstered by Regulatory approvals, Product Launches, Collaborations, and Strong R&D.
Seed Health, Inc. (US)
Seed Health offers unique products such as Synbiotics in their portfolio which makes them stand out from the herd. Apart from their product offerings seed health also has various collaborations such as their collaboration with the Swiss Institute of Allergy and Asthama Research (SAIF) which enabled them to launch their Platform to develop next-generation human microbiome products, agreements and several products in pre-clinical phases which makes them a leader in Human Microbiome Market.
Get 10% Free Customization on this Report
Content Source:
https://www.marketsandmarkets.com/ResearchInsight/human-microbiome-market.asp
https://www.marketsandmarkets.com/PressReleases/human-microbiome.asp
Comments
0 comment